The Vpu protein: New concepts in virus release and CD4 down-modulation

Current HIV Research

Volumn 8, Issue 3, 2010, Pages 240-252

  Ruiz, Autumn ^a   Guatelli, John C ^b   Stephens, Edward B ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

BST 2; CD4 down regulation; Enhanced virion release; HIV 1; Simian immunodeficiency virus; Vpu

Indexed keywords

CD4 ANTIGEN; F BOX PROTEIN; ION CHANNEL; LYMPHOCYTE RECEPTOR; VIRUS ENVELOPE PROTEIN; VPU PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; VIRULENCE FACTOR; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; ROUGH ENDOPLASMIC RETICULUM; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; DOWN REGULATION; PATHOGENICITY; PHYSIOLOGY; VIRUS RELEASE;

ANIMALS; ANTIGENS, CD4; DOWN-REGULATION; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRULENCE FACTORS; VIRUS RELEASE;

EID: 77954082342     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791111124     Document Type: Review

References (102)

1. Cohen EA, Terwilliger EF, Sodroski JG, Haseltine WA. Identification of a protein encoded by the vpu gene of HIV-1. Nature 1988; 334(6182): 532-4.
2. Strebel K, Klimkait T, Martin MA. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988; 241(4870): 1221-3.
3. Barlow KL, Ajao AO, Clewley JP. Characterization of a novel simian immunodeficiency virus (SIVmonNG1) genome sequence from a mona monkey (Cercopithecus mona). J Virol 2003; 77(12): 6879-88.
4. Courgnaud V, Salemi M, Pourrut X, et al. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny. J Virol 2002; 76(16): 8298-309.
5. Dazza MC, Ekwalanga M, Nende M, et al. Characterization of a novel vpu-harboring simian immunodeficiency virus from a Dent's Mona monkey (Cercopithecus mona denti). J Virol 2005; 79(13): 8560-71.
6. Van Heuverswyn F, Li Y, Neel C, et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006; 444(7116): 164.
7. Gomez LM, Pacyniak E, Flick M, et al. Vpu-mediated CD4 downregulation and degradation is conserved among highly divergent SIV(cpz) strains. Virology 2005; 335(1): 46-60.
8. McCormick-Davis C, Dalton SB, Singh DK, Stephens EB. Comparison of Vpu sequences from diverse geographical isolates of HIV type 1 identifies the presence of highly variable domains, additional invariant amino acids, and a signature sequence motif common to subtype C isolates. AIDS Res Hum Retrovirology 2000; 16(11): 1089-95.
9. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 1990; 64(2): 621-9.
10. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992; 66(12): 7193-200.
11. Maldarelli F, Chen MY, Willey RL, Strebel K. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol 1993; 67(8): 5056-61.
12. Schubert U, Schneider T, Henklein P, et al. Humanimmunodeficiency- virus-type-1-encoded Vpu protein is phosphorylated by casein kinase II. Euro J Biochem 1992; 204(2): 875-83.
13. Park SH, Opella SJ. Tilt angle of a trans-membrane helix is determined by hydrophobic mismatch. J Mol Biol 2005; 350(2): 310-8.
14. Park SH, Mrse AA, Nevzorov AA, et al. Three-dimensional structure of the channel-forming trans-membrane domain of virus protein u (Vpu) from HIV-1. J Mol Biol 2003; 333(2): 409-24.
15. Gonzalez ME, Carrasco L. Viroporins. FEBS Lett 2003; 552(1): 28-34.
16. Ewart GD, Sutherland T, Gage PW, Cox GB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1996; 70(10): 7108-15.
17. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, Henklein P, Strebel K, Montal M. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett 1996; 398(1): 12-8.
18. Cordes FS, Kukol A, Forrest LR, Arkin IT, Sansom MS, Fischer WB. The structure of the HIV-1 Vpu ion channel: modelling and simulation studies. Biochim et Biophys Acta 2001; 1512(2): 291-8.
19. Cordes FS, Tustian AD, Sansom MS, Watts A, Fischer WB. Bundles consisting of extended transmembrane segments of Vpu from HIV-1: computer simulations and conductance measurements. Biochemistry 2002; 41(23): 7359-65.
20. Grice AL, Kerr ID, Sansom MS. Ion channels formed by HIV-1 Vpu: a modelling and simulation study. FEBS Lett 1997; 405(3): 299-304.
21. Lopez CF, Montal M, Blasie JK, Klein ML, Moore PB. Molecular dynamics investigation of membrane-bound bundles of the channel-forming transmembrane domain of viral protein U from the human immunodeficiency virus HIV-1. Biophys J 2002; 83(3): 1259-67.
22. Sansom MS, Forrest LR, Bull R. Viral ion channels: molecular modeling and simulation. Bioessays 1998; 20(12): 992-1000.
23. Wray V, Kinder R, Federau T, Henklein P, Bechinger B, Schubert U. Solution structure and orientation of the transmembrane anchor domain of the HIV-1-encoded virus protein U by high-resolution and solid-state NMR spectroscopy. Biochemistry 1999; 38(16): 5272-82.
24. Ewart GD, Mills K, Cox GB, Gage PW. Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Euro Biophys J 2002; 31(1): 26-35.
25. Ewart GD, Nasr N, Naif H, Cox GB, Cunningham AL, Gage PW. Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob Agents Chemother 2004; 48(6): 2325-2330.
26. Okada A, Miura T, Takeuchi H. Protonation of histidine and histidine-tryptophan interaction in the activation of the M2 ion channel from influenza a virus. Biochemistry 2001; 40(20): 6053-60.
27. Takeuchi H, Okada A, Miura T. Roles of the histidine and tryptophan side chains in the M2 proton channel from influenza A virus. FEBS Lett 2003; 552(1): 35-8.
28. Tang Y, Zaitseva F, Lamb RA, Pinto LH. The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue. J Biol Chem 2002; 277(42): 39880-6.
29. Holsinger LJ, Lamb RA. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991; 183(1): 32-43.
30. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994; 68(3): 1551-63.
31. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69(3): 517-28.
32. Hout DR, Gomez ML, Pacyniak E, et al. Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques. Virology 2006; 344(2): 541-59.
33. Hout DR, Gomez LM, Pacyniak E, Miller JM, Hill MS, Stephens EB. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine. Virology 2006; 348(2): 449-61.
34. Park SH, Opella SJ. Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs. Protein Sci 2007; 16(10): 2205-15.
35. Crise B, Buonocore L, Rose JK. CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol 1990; 64(11): 5585-93.
36. Jabbar MA, Nayak DP. Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. J Virol 1990; 64(12): 6297-304.
37. Levesque K, Zhao YS, Cohen EA. Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem 2003; 278(30): 28346-53.
38. Stevenson M, Meier C, Mann AM, Chapman N, Wasiak A. Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS. Cell 1988; 53(3): 483-96.
39. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol 1992; 66(1): 226-34.
40. Schubert U, Bour S, Ferrer-Montiel AV, Montal M, Maldarell F, Strebel K. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 1996; 70(2): 809-19.
41. Vincent MJ, Raja NU, Jabbar MA. Human immunodeficiency virus type 1 Vpu protein induces degradation of chimeric envelope glycoproteins bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic domain in Vpu-induced degradation in the endoplasmic reticulum. J Virol 1993; 67(9): 5538-49.
42. Wildum S, Schindler M, Munch J, Kirchoff F. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 2006; 80(16): 8047-59.
43. Yao XJ, Garzon S, Boisvert F, Haseltine WA, Cohen EA. The effect of vpu on HIV-1-induced syncytia formation. J Acquir Immune Defic Syndr 1993; 6(2): 135-41.
44. Cortes MJ, Wong-Staal F, Lama J. Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells. J Biol Chem 2002; 277(3): 1770-9.
45. Tanaka M, Ueno T, Nakahara T, Sasaki K, Ishimoto A, Sakai H. Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1. Virology 2003; 311(2): 316-25.
46. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350(6318): 508-11.
47. Piguet V, Chen YL, Mangasarian A, Foti M, Carpentier JL, Trono D. Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes. EMBO J 1998; 17(9): 2472-81.
48. Piguet V, Gu F, Foti M, Demaurex N, Gruenberg J, Carpentier JL, Trono D. Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 1999; 97(1): 63-73.
49. Bour S, Schubert U, Strebel K. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol 1995; 69(3): 1510-20.
50. Chen MY, Maldarelli F, Karczewski MK, Willey RL, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J Virol 1993; 67(7): 3877-84.
51. Lenburg ME, Landau NR. Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol 1993; 67(12): 7238-45.
52. Buonocore L, Turi TG, Crise B, Rose JK. Stimulation of heterologous protein degradation by the Vpu protein of HIV-1 requires the transmembrane and cytoplasmic domains of CD4. Virology 1994; 204(1): 482-6.
53. Schubert U, Henklein P, Boldyreff B, Wingender E, Strebel K, Porstmann T. The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turnalpha- helix-motif. J Mol Biol 1994; 236(1): 16-25.
54. Tiganos E, Yao X, Friborg J, Daniel N, Cohen EA. Putative alphahelical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule. J Virol 1997; 71(6): 4452-60.
55. Pacyniak E, Gomez ML, Gomez LM, et al. Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi complex and its absence in the Vpu protein from a subtype C HIV-1. AIDS Res Hum Retroviruses 2005; 21(5): 379-94.
56. Hill MS, Ruiz A, Schmitt K, Stephens EB. Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression. Virology 2010; 397(1): 104-12.
57. Paul M, Jabbar MA. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpumediated ER degradation of CD4. Virology 1997; 232(1): 207-16.
58. Binette J, Dube M, Mercier J, Halawani D, Latterich M, Cohen EA. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology 2007; 4: 75.
59. Margottin F, Bour SP, Durand H, et al. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998; 1(4): 565-74.
60. Coadou G, Gharbi-Benarous J, Megy S, et al. NMR studies of the phosphorylation motif of the HIV-1 protein Vpu bound to the Fbox protein beta-TrCP. Biochemistry 2003; 42(50): 14741-51.
61. Evrard-Todeschi N, Gharbi-Benarous J, Bertho G, et al. NMR studies for identifying phosphopeptide ligands of the HIV-1 protein Vpu binding to the F-box protein beta-TrCP. Peptides 2006; 27(1): 194-210.
62. Megy S, Bertho G, Gharbi-Benarous J, et al. STD and TRNOESY NMR studies on the conformation of the oncogenic protein betacatenin containing the phosphorylated motif DpSGXXpS bound to the beta-TrCP protein. J Biol Chem 2005; 280(32): 29107-16.
63. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 2003; 11(6): 1445-56.
64. Besnard-Guerin C, Belaidouni N, Lassot I, et al. HIV-1 Vpu sequesters beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCFbetaTrCP substrates. J Biol Chem 2004; 279(1): 788-95.
65. Butticaz C, Michielin O, Wyniger J, Telenti A, Rothenberger S. Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J Virol 2007; 81(3): 1502-5.
66. Meusser B, Sommer T. Vpu-mediated degradation of CD4 reconstituted in yeast reveals mechanistic differences to cellular ER-associated protein degradation. Mol Cell 2004; 14(2): 247-58.
67. Estrabaud E, Le Rouzic E, Lopez-Verges S, et al. Regulated degradation of the HIV-1 Vpu protein through a betaTrCPindependent pathway limits the release of viral particles. PLoS Pathog 2007; 3(7): 995-1004.
68. Singh DK, Griffin DM, Pacyniak E, et al. The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4(+) T cell loss caused by the simian-human immunodeficiency virus SHIV(KU-lbMC33) in pig-tailed macaques. Virology 2003; 313(2): 435-51.
69. Ishikawa J, Kaisho T, Tomizawa H, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995; 26(3): 527-34.
70. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003; 4(10): 694-709.
71. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipidenriched membrane lipid rafts. J Virol 2000; 74(7): 3264-72.
72. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001; 98(24): 13925-30.
73. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci USA 2004; 101(41): 14889-94.
74. Dube M, Roy BB, Guiot-Guillain P, et al. Suppression of Tetherinrestricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans- Golgi network. J Virol 2009; 83(9): 4574-90.
75. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451(7177): 425-30.
76. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3(4): 245-52.
77. Jouvenet N, Neil SJ, Zhadina M, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009; 83(4): 1837-44.
78. Mitchell RS, Katsura C, Skasko MA, et al. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endolysosomal trafficking. PLoS Pathog 2009; 5(5): e10000450.
79. Perez-Caballero D, Zang T, Ebrahimi A, et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009; 139(3): 499-511.
80. Goffinet C, Allespach I, Homann S, et al. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009; 5(3): 285-97.
81. Andrew AJ, Miyagi E, Kao S, Strebel K. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009; 6: 80.
82. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009; 106(8): 2886-91.
83. Bartee E, McCormack A, Früh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2006; 2(10): e107.
84. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 2009; 5(5): e1000443.
85. Douglas JL, Viswanathan K, McCaroll MN, Gustin JK, Fruh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a{beta}TrCP-dependent mechanism. J Virol 2009; 83(16): 7931-47.
86. McNatt MW, Zang T, Hatziioannou T, et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009; 5(2): e1000300.
87. Rong L, Zhang J, Lu J, et al. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol 2009; 83(15): 7536-46.
88. Miyagi E, Andrew AJ, Kao S, Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad SciUSA 2009; 106(8): 2868-73.
89. Gummuluru S, Kinsey CM, Emerman M. An in vitro rapidturnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol 2000; 74(23): 10882-91.
90. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009; 5(9): e1000574.
91. Iwabu Y, Fujita H, Kinomoto M, et al. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 2009; 284(50): 35060-72.
92. Mansouri M, Viswanathan K, Douglas JL, et al. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 2009; 83(19): 9672-81.
93. Jia B, Serra-Moreno R, Neidermyer W, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009; 5(5): e1000429.
94. Zhang F, Wilson SJ, Landford WC, et al. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009; 6(1): 54-67.
95. Sauter D, Schindler M, Specht A, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009; 6(5): 409-21.
96. Schubert U, Strebel K. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol 1994; 68(4): 2260-71.
97. Tiganos E, Friborg J, Allain B, Daniel NG, Yao XJ, Cohen EA. Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein. Virology 1998; 251(1): 96-107.
98. Hammes SR, Dixon EP, Malim MH, Cullen BR, Greene WC. Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci USA 1989; 86(23): 9549-53.
99. Joag SV, Stephens EB, Adams RJ, Foresman L, Narayan O. Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: effects of splenectomy on virus burden. Virology 1994; 200(2): 436-46.
100. Kestler HW III, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65(4): 651-62.
101. Stephens EB, Sahni M, Leung K, Raghavan R, Joag SV, Narayan O. Nucleotide substitutions in the long terminal repeat are not required for development of neurovirulence by simian immunodeficiency virus strain mac. J Gen Virol 1998; 79(Pt 5): 1089-100.
102. Yoon K, Kestler HW, Kim S. Growth properties of HSIVnef: HIV-1 containing the nef gene from pathogenic molecular clone SIVmac239. Virus Res 1998; 57(1): 27-34.